



The University of Bradford Institutional Repository

<http://bradscholars.brad.ac.uk>

This work is made available online in accordance with publisher policies. Please refer to the repository record for this item and our Policy Document available from the repository home page for further information.

To see the final version of this work please visit the publisher's website. Available access to the published online version may require a subscription.

Link to publisher's version: <https://doi.org/10.1177/0269881117704988>

Citation: McLean SL, Harte MK, Neill JC and Young AMJ (2017) Dopamine dysregulation in the prefrontal cortex relates to cognitive deficits in the sub-chronic PCP-model for schizophrenia: a preliminary investigation. *Journal of Psychopharmacology*. 31(6): 660-666.

Copyright statement: © 2017 The Authors. Published by SAGE. Reproduced in accordance with the publisher's self-archiving policy.

Title: Dopamine dysregulation in the prefrontal cortex relates to cognitive deficits in the sub-chronic PCP-model for schizophrenia: a preliminary investigation

Running head: Prefrontal dopamine in cognitive dysfunction

Samantha L. McLean¹, Michael K. Harte², Joanna C. Neill², Andrew M.J. Young³

¹School of Pharmacy, University of Bradford, Richmond Road, BD7 1DP, UK

²Division of Pharmacy and Optometry, School of Health Sciences, University of Manchester, Oxford Road, M13 9PT, UK

³Department of Neuroscience, Psychology and Behaviour, University of Leicester, Lancaster Road, LE1 9HN, UK



Dr Samantha McLean
School of Pharmacy
The University of Bradford
Richmond Road
Bradford
BD7 1DP
UK
Tel: 01274 235809
E-mail: s.l.mclean@bradford.ac.uk

Abstract

Rationale: Dopamine dysregulation in the prefrontal cortex (PFC) plays an important role in cognitive dysfunction in schizophrenia. Sub-chronic phencyclidine (scPCP) treatment produces cognitive impairments in rodents and is a thoroughly validated animal model for cognitive deficits in schizophrenia. The aim of our study was to investigate the role of PFC dopamine in scPCP-induced deficits in a cognitive task of relevance to the disorder, novel object recognition (NOR). Methods: Twelve adult female Lister Hooded rats received scPCP (2 mg/kg) or vehicle via the intraperitoneal route twice daily for seven days, followed by seven days washout. *In vivo* microdialysis was carried out prior to, during and following the NOR task. Results: Vehicle rats successfully discriminated between novel and familiar objects and this was accompanied by a significant increase in dopamine in the PFC during the retention trial ($P < 0.01$). scPCP produced a significant deficit in NOR ($P < 0.05$ vs. control) and no PFC dopamine increase was observed. Conclusions: These data demonstrate an increase in dopamine during the retention trial in vehicle rats that was not observed in scPCP-treated rats accompanied by cognitive disruption in the scPCP group. This novel finding suggests a mechanism by which cognitive deficits are produced in this animal model and support its use for investigating disorders in which PFC dopamine is central to the pathophysiology.

Keywords: dopamine, prefrontal cortex, cognition, phencyclidine, object recognition

Introduction

The novel object recognition (NOR) task was developed by Ennaceur and Delacour and is based on the natural propensity of rats to explore novel objects (Ennaceur and Delacour, 1988). It is a non-rewarded, ethologically relevant test of visual object recognition memory (Puma et al., 1998). Indeed, NOR has been listed by the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) initiative as relevant for studying visual learning and memory deficits in schizophrenia (Young et al., 2009). Such tests of visual recognition memory are increasingly being used to detect novel drugs for improvement of cognitive dysfunction in schizophrenia and other human disorders including Alzheimer's disease, Parkinson's disease, and Autism Spectrum Disorder (Grayson et al., 2015).

The brain regions thought to be involved in object recognition memory depend on the length of the inter-trial interval (ITI). We have recently shown that normal unimpaired animals lose the ability to discriminate objects following an ITI of 6 hours (McLean et al., 2016). Rats with hippocampal lesions exhibit impairments in object recognition following long ITIs (>15 min), but not short intervals of <15 min (Clark et al., 2000). Although much of the evidence indicates a critical role for the perirhinal

cortex in object recognition memory following short ITIs (Gaffan and Murray, 1992; Meunier et al., 1993; Ennaceur et al., 1996; Brown and Aggleton, 2001; Hannesson et al., 2004), research also suggests that the prefrontal cortex (PFC) may also contribute to recognition memory. PFC neurons have been shown to relay information concerning the relative familiarity of individual stimuli (Xiang and Brown, 2004), and damage to this area has been shown to impair recognition memory (Kolb et al., 1994; Ragozzino et al., 2002). More recently, fMRI studies have demonstrated that disruption of mPFC activation is correlated with impairments in recognition memory (Zanto et al., 2011). However, there is also conflicting evidence showing that cytotoxic lesions of the mPFC spared object recognition performance following a 10 min ITI (Yee, 2000); this further highlights the need to further investigate the role of the PFC in this behavioural task.

Dysfunction in the glutamatergic system is a prominent hypothesis for the pathogenesis of schizophrenia (Olney et al., 1999). As a result of this hypothesis, many pre-clinical animal models for schizophrenia are now based on the administration of NMDA receptor antagonists such as phencyclidine, MK-801 and ketamine (Neill et al., 2014). The non-competitive NMDA receptor antagonist, phencyclidine (PCP) has been shown to produce enduring cognitive deficits similar to those observed in schizophrenia in rodents (Javitt and Zukin, 1991; Meltzer et al., 2013) particularly when administered sub-chronically-sc (Jentsch and Roth, 1999; Neill et al., 2010; Rajagopal et al., 2014; Janhunen et al., 2015). Indeed, we have consistently shown in our laboratory that a

scPCP treatment regimen produces long lasting and robust cognitive impairments in several cognitive domains of relevance to schizophrenia, including visual learning (McLean et al., 2011; Neill et al., 2016), reasoning and problem solving (McLean et al., 2012; Neill et al., 2016; McLean et al., 2010), executive function (McLean et al., 2012) and attention/vigilance (Barnes et al., 2016; Barnes et al., 2012).

While newer compounds for cognition and negative symptoms, the major unmet clinical needs in schizophrenia, targeting mechanisms such as the metabotropic glutamate receptor 2/3 subtype, phosphodiesterase subtype 10, glycine transporter subtype 1 and the $\alpha 7$ nicotinic acetylcholine receptor have been the subject of intense drug discovery and development efforts; there is still a lack of success in Phase III clinical trials (Dunlop and Brandon, 2015), Dopamine hypofunction in the PFC is thought to have a major role in the aetiology of negative symptoms and cognitive dysfunction in schizophrenia (Jentsch and Roth, 1999; Abi-Dargham and Moore, 2003; Goldman-Rakic et al., 2004; Stone et al., 2007). scPCP has been shown to reduce dopamine utilisation in the PFC and nucleus accumbens (Jentsch et al., 1997). Furthermore, it has been shown that the atypical antipsychotics, sertindole and risperidone, increase extracellular dopamine in rat mPFC and nucleus accumbens (Mork et al., 2009) and improve a scPCP-induced deficit in NOR memory (Grayson et al., 2007; Idris et al., 2010). We have also previously shown that targeting dopamine D₁ receptors ameliorates the effects of scPCP treatment in NOR, reversal learning and the 5

choice continuous performance test (McLean et al., 2009; Barnes et al., 2016), further implicating the role of dopamine in prefrontal-based cognitive tasks.

As yet, the role of dopamine in scPCP-induced cognitive disruption remains to be fully established. Therefore, the aim of this study was to investigate the interaction between the NOR deficit induced by our scPCP treatment regime and levels of PFC dopamine. This was achieved by combining *in vivo* microdialysis in freely moving behaving animals to assess the changes in PFC dopamine at the same time as observing a cognitive deficit.

Materials and Methods

Subjects and drug treatment

Twelve adult female Lister Hooded rats (Charles River, UK) were housed in groups of 2-3 and weighed 220-250 g at the start of the dosing regimen and 240-270 g at the time of surgery and behavioural testing. Animals were housed under standard laboratory conditions at a temperature of 20°C ($\pm 1^\circ\text{C}$) and humidity of 50 \pm 5%. They were maintained on a 12-h/12-h light/dark cycle (lights on at 0700 hours) and experimental procedures were performed during the light phase. Rats had free access to food and water at all times, except during NOR testing and habituation. Rats were treated with 2 mg/kg PCP (phencyclidine hydrochloride, Sigma, UK; $n = 5$) or vehicle (0.9 % saline; $n = 7$), twice daily for 7 days; this was followed by a 7-day washout period. All

experiments were performed according to the Animals (Scientific Procedures) Act, 1986, and with approval from the University of Leicester Animal Ethics Committee.

Surgery and microdialysis

Rats were anaesthetised with isoflurane (1-3% isoflurane in O₂: 1 litre/min) and stainless steel guide cannulae (o.d., 890 µm; i.d., 685 µm; length 10 mm: Coopers Needle Works, Birmingham, UK) were stereotaxically implanted into the brain, aimed at the PFC, figure 1. Following recovery from surgery (≥ 7 days), dialysis probes were inserted into the guide cannulae to lie in the PFC with stereotaxic co-ordinates (tip position mm from Bregma: H, +3.2; Tr, -0.5; V, -5.4; (Paxinos and Watson, 1998)). Microdialysis probes were constructed in house and checked for flow rate integrity and leaks before implantation (Young et al., 1998). At least one hour after implantation of the probe, animals were connected to the delivery system, and perfusion with artificial cerebrospinal fluid (mM: NaCl, 145; KCl, 3.3; MgSO₄, 2.4; KH₂PO₄, 1.25; CaCl₂, 1.85: 2 µl/min flow rate) commenced immediately. Following equilibration for 1 hour, dialysate samples were collected consecutively for 10 min into 2 µl of 1.0 M H₃PO₄ (to minimise oxidation). The first four samples (40 min) were used to determine basal dopamine levels in the dialysates. Samples were then collected during the NOR test during the 10 min habituation to the box, acquisition, inter-trial interval (ITI) and retention phases (all 10 min); in addition, 3 samples were collected post-testing (30

min). At the end of the collection period, animals were killed by anaesthetic overdose (sodium pentobarbitone, JML, Southampton, UK) and cervical dislocation. The brains were removed and stored in 4% formalin and placement of the probes confirmed using cresyl violet staining.

Novel object recognition testing

Rats were tested in the NOR task as described in detail previously (McLean et al., 2011), with the exception that 10-min trials were used with a 10 min ITI (not 3-min trials with a 1 min ITI our usual protocol) in order to give enough time to collect the required sample for HPLC analysis. Rats were habituated to the test arena for 30 min for 3 days prior to the test day. Following a 10-min habituation session on the day of testing, each rat was placed in the NOR chamber and exposed to two identical objects for a period of 10 min. The rats were then returned to their home cage for an ITI of 10 min; the entire box was cleaned with 10% ethanol, both objects removed and one replaced with an identical familiar copy and one with a novel object. Following the ITI, rats were returned to explore the familiar and a novel object in the test arena for a 10-min retention trial. All experiments were video recorded for subsequent behavioural analysis by an experimenter blinded to the treatment. Locomotor activity was also recorded; this was evaluated by scoring the total number of sectors or line crossings by the animal in acquisition and retention trial. The exploration time (s) of each object in

each trial was recorded manually using two stopwatches and the discrimination index (DI) was calculated: $DI = (\text{time exploring the novel object (s)} - \text{time exploring the familiar object}) / \text{total time exploring both novel and familiar objects}$. The DI represents the difference in exploration time expressed as a proportion of the total time spent exploring the two objects in the retention trial. A value of 1 would show that rats explored only the novel object; a value of -1 would show that rats only explored the familiar object and a value of 0 indicates exploration of both objects equally.

HPLC detection of dopamine

After collection, all dialysate samples (1-11) were analysed to determine the concentration of dopamine in each sample by HPLC with electrochemical detection. Samples (15 μl) were injected onto the column using a Spark Triathlon refrigerated autosampler (Presearch, UK). The mobile phase consisted of 75 mM NaH_2PO_4 , 1.1 mM octanesulfonic acid, 1 mM EDTA, 10% methanol, pH 3.7 and was pumped at 110 $\mu\text{l}/\text{min}$ using a Rheos 4000A pump (Presearch, UK), and separation was achieved using a 150 mm \times 1.0 mm LUNA C18(2) 5 μm column (Phenomenex, UK). Dopamine (retention time of approximately 12 min) concentrations were calculated with reference to standards at 1, 10, and 100 nM. Data were collected and analyzed using Chrom Perfect Analysis v5.5.4 (Justice Laboratories, NJ, USA) PC-based integrator. All chemicals were supplied by Sigma Chemicals (Poole, UK) and were HPLC grade.

Data and statistical analysis

The NOR data are expressed as mean exploration time \pm S.E.M. Student's paired t-test was performed to compare time spent exploring the familiar versus the novel object. The discrimination index (DI) values are expressed as mean \pm S.E.M. Locomotor activity (LMA) data are expressed as mean \pm S.E.M of the total number of lines crossed during the acquisition and retention trials. Analysis of the DI values and total LMA were performed using independent t-tests, vehicle compared with the scPCP group.

The basal concentration of dopamine was calculated from the four samples taken prior to behavioural testing; subsequent samples were then expressed as percent of basal. Microdialysis data were analysed using a repeated measures two-way ANOVA with stage of task as a within subjects factor (habituation, acquisition, ITI, retention, 3 post-test) and treatment (vehicle or scPCP) as a between subjects factor. This was followed by planned pair-wise comparisons with Bonferroni adjustment. All statistical analyses were performed using SPSS (version 22).

Results

Initially the groups consisted of 7 vehicle-treated and 5 scPCP-treated rats; however 2 vehicle-treated rats were excluded due to technical problems with HPLC, these rats were removed from all analyses, therefore the final treatment groups were both n=5.

Following cresyl violet staining, the locations of the probes were verified. All probes were located within the PFC at Bregma 2.7 to 3.2 mm. An example image of probe location is shown in figure 1.

Paired t-tests revealed that there was no significant difference between the time spent exploring the two identical objects during the acquisition trial in either vehicle or scPCP-treated rats (data not shown). In the retention trial, vehicle-treated rats explored the novel object more than the familiar object, although this effect was not significant ($P = 0.11$; table 1); there was no significant difference in exploration of the novel and familiar object in scPCP-treated rats (table 1). However, an independent t-test revealed a significant difference in the DI ($t[9] = 2.87$; $P = 0.018$). The DI for the scPCP-treated group was significantly reduced from 0.60 in the vehicle treated group to 0.25 (figure 2). Moreover, one-sample t-tests showed that the DI was significantly different from zero (no discrimination) in the saline treated animals ($t[5] = 8.41$; $P < 0.001$), but not in the scPCP pre-treated group ($t[4] = 2.34$; $P = 0.78$). Independent t-tests showed no significant effect on locomotor activity assessed by the total number of line crossings in the acquisition and retention trials (76.5 ± 19.6 in vehicle-treated rats compared to 97 ± 16.9 in scPCP-treated rats; data not shown).

Following the behavioural experiments, HPLC was carried out, therefore the groups for dopamine analysis were vehicle ($n=5$) and scPCP ($n=5$). The mean of the 4 baseline concentrations prior to behavioural testing was calculated. An independent t-

test revealed no significant difference between basal levels in the two groups (vehicle, 3.3 ± 2.0 nM; scPCP, 2.9 ± 0.6 nM). Data were subsequently expressed as percent of basal (figure 3). A two-way repeated measures ANOVA with stage of test as the within subjects factor and treatment as the between subjects factor revealed no significant interaction ($F_{[4,32]} = 1.89$; $P = 0.13$). However, planned pair-wise comparisons with Bonferroni adjustment revealed a selective and significant increase in dopamine levels in vehicle treated rats in the retention phase compared to basal (290 ± 120 % of basal; $P < 0.01$), however, this effect was not observed in scPCP-treated rats (113 ± 19 % of basal).

Discussion

This study aimed to investigate the role of prefrontal dopamine in deficits in NOR task performance in the scPCP animal model for schizophrenia. The main findings suggest that an increase in dopamine in the PFC during the retention trial may be beneficial for NOR performance either by increasing the preference for the novel object or for aiding the recall of memory for the familiar object. During the acquisition trial of the NOR task there was no difference in the exploration time of the two identical objects in either vehicle or scPCP-treated rats. Conversely, in the retention trial, calculation of the DI revealed that vehicle-treated rats could discriminate the novel from familiar object in the retention trial, suggesting that they remembered the familiar object. However, this

discrimination was not observed when comparing time spent at the novel versus the familiar object; this lack of discrimination is likely due to the low n numbers and subsequent large variability within the group. In the scPCP-treated rats however, the object exploration data and the DI revealed that rats could not discriminate between the novel and familiar objects, suggesting that scPCP-treated rats did not remember the familiar object. This scPCP-induced deficit in NOR (and its attenuation by dopamine/serotonin receptor antagonist drugs for schizophrenia and novel targets) is supported by many previous studies in our laboratory (McLean et al., 2011; Neill et al., 2010; Neill et al., 2016) and elsewhere. These results are also consistent with previous reports from others demonstrating scPCP treatment in rats impairs object recognition (Le Cozannet et al., 2010; Redrobe et al., 2012; Miyauchi et al., 2016). In addition, it has been shown that PCP, when given in varying dosing regimens, produced deficits in object recognition in mice (Nagai et al., 2009; Hashimoto et al., 2005; Horio et al., 2013; Rajagopal et al., 2016).

The concentration of dopamine in the PFC revealed that the basal levels in vehicle and scPCP-treated rats were similar. Concentrations were also comparable during all stages of the NOR task with the exception of the retention trial, in which a large increase in dopamine was observed in the vehicle treated group. This suggests that dopamine in the PFC is important for retrieval of object recognition memory, not encoding or consolidation, as levels remained comparable to baseline during the

acquisition trial and ITI. In contrast, this increase in prefrontal dopamine was absent in the scPCP-treated group. In collaboration with the Meltzer laboratory we conducted a similar study some years ago (published in abstract form only). There were some differences as in that study we used female Long Evans rats, 15 min time bins, also investigated hippocampus and did not include so many time points (Snigdha et al., 2008). However, our current findings confirm that early result and show impaired performance in retention accompanied by a lack of increase in dopamine in the PFC.

It has been shown that many dopamine/serotonin receptor antagonist drugs for schizophrenia such as sertindole and risperidone (Mork et al., 2009), and clozapine, olanzapine and quetiapine (Tanda et al., 2015) increase extracellular dopamine in male rat mPFC. More specifically, we have shown that intracortical perfusion of the dopamine D₁-like receptor agonist, SKF-38393, in drug-naïve awake male rats decreased glutamate and increased GABA release in the mPFC, potentially restoring the balance between glutamate and GABA (Harte and O'Connor, 2004). We have also established that SKF-38393, when given systemically, can reverse the scPCP-induced deficit in NOR in female rats (McLean et al., 2009). This is supported by data reporting that microinfusion of the dopamine D₁-like receptor antagonist SCH-23390 into the rat mPFC produced a deficit in NOR (Rossato et al., 2013; Clausen et al., 2011). Conversely in a recent study, microinfusion of the D₁-like receptor agonist SKF81297 into the mPFC induced a dose-related impairment in object recognition encoding and

retrieval (Pezze et al., 2015). Although these results appear conflicting, the authors propose that NOR memory requires an optimal level of D₁ receptor stimulation in the mPFC and may reflect an inverted U-shaped function (Pezze et al., 2015). The role of dopamine in the PFC has been further investigated using other selective dopamine receptor agonists and antagonists. Bilateral microinjection of the dopamine D₃ antagonist, S33084, into the rat PFC caused a dose-related improvement in NOR, while intra-striatal injection had no effect (Watson et al., 2012). In contrast, bilateral microinjection of the preferential D₂ antagonist, L741,626, into the PFC (but not striatum) caused a dose-related impairment in NOR in rats (Watson et al., 2012). Taken together, these results show that pharmacological manipulation of dopamine levels in the PFC can have either beneficial or detrimental effects on object recognition memory, in that they follow an inverted U-shaped relationship.

One limitation of the present study is low n numbers, as two vehicle-treated rats had to be excluded from the final analysis due technical problems with the HPLC analysis; therefore, the final number of rats (5 vehicle and 5 PCP) was low for a behavioural study. Previous studies in this laboratory have found a robust and reproducible deficit with scPCP in NOR when using 8-10 rats (Neill et al., 2010). Due to the low number of rats used here, the error within the groups is large; this is particularly apparent in the vehicle group during exploration of the novel object and may explain the lack of a significant difference in exploration times in the retention

trial. However, this is a preliminary study and clearly requires verification with a larger sample size and more detailed analysis of other neurotransmitters.

In summary, these current results demonstrate recruitment of dopamine in the PFC when rats are exposed to two objects, one new and one familiar. As there was no increase in PFC dopamine in the acquisition trial, these new, but preliminary, data support the hypothesis that, for rats to recall information about the familiar object they must recruit PFC dopamine, an effect which is absent in scPCP treated rats which may explain why they cannot discriminate the novel from familiar object. A link between dopamine and cognition has been observed in patients with schizophrenia, in that low dopamine turnover was associated with poor verbal recall (Oades et al., 2005), albeit dopamine was measured in plasma and not brain. In conclusion our findings provide evidence that the scPCP model has considerable validity for investigating cognitive deficits in schizophrenia. Furthermore, the ability of novel compounds to restore this PFC dysfunction (and the NOR deficit) may well reveal compounds with good efficacy in the clinic to overcome cognitive disturbances observed in schizophrenia, a current unmet need.

Funding

SLM was supported by a joint GSK and University of Bradford PhD studentship at the time this work was carried out and is now supported by a Royal Society research grant (RG160255) and an Alzheimer's Research UK equipment grant (ARUK-EG-2016A-3).

AMJY would like to acknowledge the benefit of a period of study leave granted by the University of Leicester to facilitate completion of this work. JCN and MKH are full time employees of the University of Manchester.

Declaration of conflicting interests

The authors declare that there is no conflict of interest.

Table and Figures

Table 1: The effect of treatment with vehicle or scPCP on exploration times of objects in the NOR task

Group	Exploration time (s)			
	Acquisition		Retention	
	Left	Right	Novel	Familiar
Vehicle	20.7 ± 6.6	19.8 ± 5.1	24.7 ± 11.4	6.0 ± 2.3
PCP	24.8 ± 3.6	24.2 ± 3.5	27.0 ± 6.2	17.2 ± 4.0

Figure 1





Figure 2





Figure 3



Legends

Table 1: The effect of treatment with vehicle or scPCP (2 mg/kg, twice daily for 7 days, i.p. followed by 7 days drug free) in the NOR task. Data are shown as mean exploration times \pm s.e.m (n=5 per group). There were no significant differences between time spent exploring the novel and familiar object in either treatment group.

Figure 1: Microdialysis probe placement. Top: coronal image from Watson and Paxinos (1998), Bregma 2.7 mm showing PFC regions. Bottom: Photograph taken at x4 magnification following Cresyl violet staining. The solid shaded rectangle represents the position of the cannula; the dotted line represents the tip position.

Figure 2: The effect of treatment with vehicle or scPCP (2 mg/kg, twice daily for 7 days, i.p. followed by 7 days drug free) in the NOR task. Data are shown as mean DI \pm s.e.m (n=5 per group). The DI for the scPCP-treated group was significantly reduced compared to the vehicle group (*P<0.05).

Figure 3: Relative concentrations of dopamine in the PFC expressed as percent basal in vehicle and scPCP-treated rats at each stage of the NOR task. Data are shown as mean

percent of basal \pm S.E.M (n=5). **P<0.01 significant increase in dopamine in the retention phase compared to basal level.

References

- Abi-Dargham A and Moore H. (2003) Prefrontal DA transmission at D1 receptors and the pathology of schizophrenia. *Neuroscientist* 9: 404-416.
- Barnes SA, Young JW, Bate ST, et al. (2016) Dopamine D1 receptor activation improves PCP-induced performance disruption in the 5C-CPT by reducing inappropriate responding. *Behav Brain Res* 300: 45-55.
- Barnes SA, Young JW and Neill JC. (2012) D(1) receptor activation improves vigilance in rats as measured by the 5-choice continuous performance test. *Psychopharmacology (Berl)* 220: 129-141.
- Brown MW and Aggleton JP. (2001) Recognition memory: what are the roles of the perirhinal cortex and hippocampus? *Nat Rev Neurosci* 2: 51-61.
- Clark RE, Zola SM and Squire LR. (2000) Impaired recognition memory in rats after damage to the hippocampus. *J Neurosci* 20: 8853-8860.
- Clausen B, Schachtman TR, Mark LT, et al. (2011) Impairments of exploration and memory after systemic or prelimbic D1-receptor antagonism in rats. *Behav Brain Res* 223: 241-254.
- Dunlop J and Brandon NJ. (2015) Schizophrenia drug discovery and development in an evolving era: Are new drug targets fulfilling expectations? *J Psychopharmacol* 29.
- Ennaceur A and Delacour J. (1988) A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data. *Behav Brain Res* 31: 47-59.
- Ennaceur A, Neave N and Aggleton JP. (1996) Neurotoxic lesions of the perirhinal cortex do not mimic the behavioural effects of fornix transection in the rat. *Behav Brain Res* 80: 9-25.
- Gaffan D and Murray EA. (1992) Monkeys (*Macaca fascicularis*) with rhinal cortex ablations succeed in object discrimination learning despite 24-hr intertrial

- intervals and fail at matching to sample despite double sample presentations. *Behav Neurosci* 106: 30-38.
- Goldman-Rakic PS, Castner SA, Svensson TH, et al. (2004) Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. *Psychopharmacology (Berl)* 174: 3-16.
- Grayson B, Idris NF and Neill JC. (2007) Atypical antipsychotics attenuate a sub-chronic PCP-induced cognitive deficit in the novel object recognition task in the rat. *Behav Brain Res* 184: 31-38.
- Grayson B, Leger M, Piercy C, et al. (2015) Assessment of disease-related cognitive impairments using the novel object recognition (NOR) task in rodents. *Behav Brain Res* 285: 176-193.
- Hannesson DK, Howland JG and Phillips AG. (2004) Interaction between perirhinal and medial prefrontal cortex is required for temporal order but not recognition memory for objects in rats. *J Neurosci* 24: 4596-4604.
- Harte M and O'Connor WT. (2004) Evidence for a differential medial prefrontal dopamine D1 and D2 receptor regulation of local and ventral tegmental glutamate and GABA release: a dual probe microdialysis study in the awake rat. *Brain Res* 1017: 120-129.
- Hashimoto K, Fujita Y, Shimizu E, et al. (2005) Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of clozapine, but not haloperidol. *Eur J Pharmacol* 519: 114-117.
- Horio M, Fujita Y and Hashimoto K. (2013) Therapeutic effects of metabotropic glutamate receptor 5 positive allosteric modulator CDPBB on phencyclidine-induced cognitive deficits in mice. *Fundam Clin Pharmacol* 27: 483-488.
- Idris N, Neill J, Grayson B, et al. (2010) Sertindole improves sub-chronic PCP-induced reversal learning and episodic memory deficits in rodents: involvement of 5-HT(6) and 5-HT (2A) receptor mechanisms. *Psychopharmacology (Berl)* 208: 23-36.
- Janhunen SK, Svard H, Talpos J, et al. (2015) The subchronic phencyclidine rat model: relevance for the assessment of novel therapeutics for cognitive impairment associated with schizophrenia. *Psychopharmacology (Berl)* 232: 4059-4083.
- Javitt DC and Zukin SR. (1991) Recent advances in the phencyclidine model of schizophrenia. *Am J Psychiatry* 148: 1301-1308.
- Jentsch JD and Roth RH. (1999) The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. *Neuropsychopharmacology* 20: 201-225.
- Jentsch JD, Tran A, Le D, et al. (1997) Subchronic phencyclidine administration reduces mesoprefrontal dopamine utilization and impairs prefrontal cortical-dependent cognition in the rat. *Neuropsychopharmacology* 17: 92-99.

- Kolb B, Buhrmann K, McDonald R, et al. (1994) Dissociation of the medial prefrontal, posterior parietal, and posterior temporal cortex for spatial navigation and recognition memory in the rat. *Cereb Cortex* 4: 664-680.
- Le Cozannet R, Fone KC and Moran PM. (2010) Phencyclidine withdrawal disrupts episodic-like memory in rats: reversal by donepezil but not clozapine. *Int J Neuropsychopharmacol* 13: 1011-1020.
- McLean SL, Grayson B, Idris NF, et al. (2011) Activation of alpha7 nicotinic receptors improves phencyclidine-induced deficits in cognitive tasks in rats: implications for therapy of cognitive dysfunction in schizophrenia. *Eur Neuropsychopharmacol* 21: 333-343.
- McLean SL, Grayson B, Marsh S, et al. (2016) Nicotinic alpha7 and alpha4beta2 agonists enhance the formation and retrieval of recognition memory: Potential mechanisms for cognitive performance enhancement in neurological and psychiatric disorders. *Behav Brain Res* 302: 73-80.
- McLean SL, Idris NF, Grayson B, et al. (2012) PNU-120596, a positive allosteric modulator of alpha7 nicotinic acetylcholine receptors, reverses a sub-chronic phencyclidine-induced cognitive deficit in the attentional set-shifting task in female rats. *J Psychopharmacol* 26: 1265-1270.
- McLean SL, Idris NF, Woolley ML, et al. (2009) D(1)-like receptor activation improves PCP-induced cognitive deficits in animal models: Implications for mechanisms of improved cognitive function in schizophrenia. *Eur Neuropsychopharmacol* 19: 440-450.
- McLean SL, Neill JC, Idris NF, et al. (2010) Effects of asenapine, olanzapine, and risperidone on psychotomimetic-induced reversal-learning deficits in the rat. *Behav Brain Res* 214: 240-247.
- Meltzer HY, Rajagopal L, Huang M, et al. (2013) Translating the N-methyl-D-aspartate receptor antagonist model of schizophrenia to treatments for cognitive impairment in schizophrenia. *Int J Neuropsychopharmacol* 16: 2181-2194.
- Meunier M, Bachevalier J, Mishkin M, et al. (1993) Effects on visual recognition of combined and separate ablations of the entorhinal and perirhinal cortex in rhesus monkeys. *J Neurosci* 13: 5418-5432.
- Miyauchi M, Neugebauer NM, Oyamada Y, et al. (2016) Nicotinic receptors and lurasidone-mediated reversal of phencyclidine-induced deficit in novel object recognition. *Behav Brain Res* 301: 204-212.
- Mork A, Witten LM and Arnt J. (2009) Effect of sertindole on extracellular dopamine, acetylcholine, and glutamate in the medial prefrontal cortex of conscious rats: a comparison with risperidone and exploration of mechanisms involved. *Psychopharmacology (Berl)* 206: 39-49.

- Nagai T, Murai R, Matsui K, et al. (2009) Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors. *Psychopharmacology (Berl)* 202: 315-328.
- Neill JC, Barnes S, Cook S, et al. (2010) Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism. *Pharmacol Ther* 128: 419-432.
- Neill JC, Grayson B, Kiss B, et al. (2016) Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology. *Eur Neuropsychopharmacol* 26: 3-14.
- Neill JC, Harte MK, Haddad PM, et al. (2014) Acute and chronic effects of NMDA receptor antagonists in rodents, relevance to negative symptoms of schizophrenia: a translational link to humans. *Eur Neuropsychopharmacol* 24: 822-835.
- Oades RD, Ropcke B, Henning U, et al. (2005) Neuropsychological measures of attention and memory function in schizophrenia: relationships with symptom dimensions and serum monoamine activity. *Behav Brain Funct* 1: 14.
- Olney JW, Newcomer JW and Farber NB. (1999) NMDA receptor hypofunction model of schizophrenia. *J Psychiatr Res* 33: 523-533.
- Paxinos G and Watson C. (1998) The rat brain atlas in stereotaxic coordinates. *San Diego: Academic*.
- Pezze MA, Marshall HJ, Fone KC, et al. (2015) Dopamine D1 receptor stimulation modulates the formation and retrieval of novel object recognition memory: Role of the prelimbic cortex. *Eur Neuropsychopharmacol* 25: 2145-2156.
- Puma C, Baudoin C and Bizot JC. (1998) Effects of intraseptal infusions of N-methyl-D-aspartate receptor ligands on memory in an object recognition task in rats. *Neurosci Lett* 244: 97-100.
- Ragozzino ME, Detrick S and Kesner RP. (2002) The effects of prelimbic and infralimbic lesions on working memory for visual objects in rats. *Neurobiol Learn Mem* 77: 29-43.
- Rajagopal L, Burgdorf JS, Moskal JR, et al. (2016) GLYX-13 (rapastinel) ameliorates subchronic phencyclidine- and ketamine-induced declarative memory deficits in mice. *Behav Brain Res* 299: 105-110.
- Rajagopal L, Massey BW, Huang M, et al. (2014) The novel object recognition test in rodents in relation to cognitive impairment in schizophrenia. *Curr Pharm Des* 20: 5104-5114.
- Redrobe JP, Elster L, Frederiksen K, et al. (2012) Negative modulation of GABAA alpha5 receptors by RO4938581 attenuates discrete sub-chronic and early postnatal phencyclidine (PCP)-induced cognitive deficits in rats. *Psychopharmacology (Berl)* 221: 451-468.

- Rossato JJ, Radiske A, Kohler CA, et al. (2013) Consolidation of object recognition memory requires simultaneous activation of dopamine D1/D5 receptors in the amygdala and medial prefrontal cortex but not in the hippocampus. *Neurobiol Learn Mem* 106: 66-70.
- Snigdha S, Li Z, Dai J, et al. (2008) Effect of PCP to attenuate DA efflux in rats performing the object recognition task: an in vivo investigation. *Society for Neuroscience Abstracts*.
- Stone JM, Morrison PD and Pilowsky LS. (2007) Glutamate and dopamine dysregulation in schizophrenia--a synthesis and selective review. *J Psychopharmacol* 21: 440-452.
- Tanda G, Valentini V, De Luca MA, et al. (2015) A systematic microdialysis study of dopamine transmission in the accumbens shell/core and prefrontal cortex after acute antipsychotics. *Psychopharmacology (Berl)* 232: 1427-1440.
- Watson DJ, Loiseau F, Ingallinesi M, et al. (2012) Selective blockade of dopamine D3 receptors enhances while D2 receptor antagonism impairs social novelty discrimination and novel object recognition in rats: a key role for the prefrontal cortex. *Neuropsychopharmacology* 37: 770-786.
- Xiang JZ and Brown MW. (2004) Neuronal responses related to long-term recognition memory processes in prefrontal cortex. *Neuron* 42: 817-829.
- Yee BK. (2000) Cytotoxic lesion of the medial prefrontal cortex abolishes the partial reinforcement extinction effect, attenuates prepulse inhibition of the acoustic startle reflex and induces transient hyperlocomotion, while sparing spontaneous object recognition memory in the rat. *Neuroscience* 95: 675-689.
- Young AM, Ahier RG, Upton RL, et al. (1998) Increased extracellular dopamine in the nucleus accumbens of the rat during associative learning of neutral stimuli. *Neuroscience* 83: 1175-1183.
- Young JW, Powell SB, Risbrough V, et al. (2009) Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia. *Pharmacol Ther* 122: 150-202.
- Zanto TP, Rubens MT, Thangavel A, et al. (2011) Causal role of the prefrontal cortex in top-down modulation of visual processing and working memory. *Nat Neurosci* 14: 656-661.